Reframe Cancer today announces the appointment of Professor Ben Kelly as its new Chief Operating Officer. He joins Reframe Cancer from Nuffield Health, where he enjoyed a ten year tenure within the senior leadership team.
Professor Ben Kelly is a multi-award winning healthcare leader, having most recently embedded data and evidence first approaches across Nuffield Health, this directly facilitated the delivery of industry leading clinical outcomes and operational excellence. He is also a world leader in the design and delivery of care pathways with a particular focus on primary and secondary prevention.
Ben has worked within healthcare and clinical research for the entirety of his career both clinically within cardiology as well as strategically across governmental groups and the independent sector. He has also led several functions including clinical research & innovation, data science, clinical outcomes & impact and operational excellence.
Professor Ben Kelly, Chief Operating Officer at Reframe Cancer commented: "I'm incredibly excited to join an organisation with such a strong purpose and focus. The opportunity to improve the quality of life of cancer patients is an honour and is something I am 100% motivated by and committed to. What the cancer nurse specialists and support managers achieve for patients at Reframe is amazing. I aim to do all I can to support these teams and positively contribute to the growth of this incredible organisation whilst keeping the patient front and centre.”
Mark Stephenson, CEO at Reframe Cancer commented: “We’re naturally thrilled that Professor Ben Kelly has joined Reframe Cancer as Chief Operating Officer. His experience and clinical data expertise will facilitate Reframe Cancer in supporting even more patients as well as delivering industry leading outcomes. Ben is another senior hire that reflects not just Reframe’s growth and strength, but its commitment to delivering the highest level of clinical excellence for cancer patients.”